Cost-effectiveness analysis of molecular diagnosis by next-generation sequencing versus sequential single testing in metastatic non-small cell lung cancer patients from a south Spanish hospital perspective

References

• Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet [Internet]. 2017;389(10066):299–311.
   PubMed Web of Science ®Google Scholar
• Seom.org. [ cited 2021 Dec 10]. Available from: https://seom.org/seomcms/images/stories/recursos/Cifras_del_cancer_2020.pdf
   Google Scholar
• Griffin R, Ramirez RA. Molecular targets in non-small cell lung cancer. Ochsner J. 2017;17(4):388–392. Winter
   PubMed Web of Science ®Google Scholar
• Besse B, Adjei A, Baas P, et al. 2nd ESMO consensus conference on lung cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann Oncol [Internet]. 2014;25:1475–1484.
   PubMed Web of Science ®Google Scholar
• Brown NA, Aisner DL, Oxnard GR. Precision medicine in non-small cell lung cancer: current standards in pathology and biomarker interpretation. Am Soc Clin Oncol Educ Book.[Internet]. 2018;38(38):708–715.
   PubMedGoogle Scholar
• Russo A, Lopes AR, McCusker MG, et al. New targets in lung cancer (excluding EGFR, ALK, ROS1). Curr Oncol Rep [Internet]. 2020;22(5):48.
   PubMed Web of Science ®Google Scholar
• Rebuzzi SE, Zullo L, Rossi G, et al. Novel emerging molecular targets in non-small cell lung cancer. Int J Mol Sci [Internet]. 2021;22(5):2625.
   PubMed Web of Science ®Google Scholar
• *Tan AC, Lai GGY, Tan GS, et al. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: incremental yield of actionable alterations and cost-effectiveness analysis. Lung Cancer [Internet]. 2020;139:207–215.
   PubMed Web of Science ®Google Scholar
• **Pennell NA, Mutebi A, Zhou Z-Y, et al. Economic impact of next-generation sequencing versus single-gene testing to detect genomic alterations in metastatic non–small-cell lung cancer using a decision analytic model. JCO Precis Oncol [Internet]. 2019;3:1–9.
   Web of Science ®Google Scholar
• Fumagalli C, Barberis M. Diagnostic and predictive biomarkers in lung cancer. Cancers (Basel) [Internet]. 2021;13(11):2577.
   PubMed Web of Science ®Google Scholar
• Garrido P, Conde E, de Castro J, et al. Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol [Internet]. 2020;22(7):989–1003.
   PubMed Web of Science ®Google Scholar
• ESMO. ESMO issues first recommendations on using next-generation sequencing for advanced cancers [ESMO press release] [Internet]. Esmo.org. [ cited 2021 Dec 10]. Available from: https://www.esmo.org/newsroom/press-office/esmo-issues-first-recommendations-on-using-next-generation-sequencing-for-advanced-cancers
   Google Scholar
• **Salas C, Martín-López J, Martínez-Pozo A, et al. Real-world biomarker testing rate and positivity rate in NSCLC in Spain: prospective central lung cancer biomarker testing registry (LungPath) from the Spanish Society of Pathology (SEAP). J Clin Pathol [Internet]. 2021. jclinpath2020207280. . jclinpath2020207280. 10.1136/jclinpath-2020-207280.
   Web of Science ®Google Scholar
• Finn S, Addeo A, Dafni U, et al. Prognostic impact of KRAS G12C mutation in patients with NSCLC: results from the European thoracic oncology platform lungscape project. J Thorac Oncol. 2021;16(6):990–1002.
   PubMed Web of Science ®Google Scholar
• Chouaid C, Agulnik J, Goker E, et al. Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: a prospective cross-sectional patient survey in a real-world setting. J Thorac Oncol [Internet]. 2013;8(8):997–1003.
   PubMed Web of Science ®Google Scholar
• ThermoFisher Scientific. Oncomine Focus Assay [Internet]. [cited 2022 Apr 21]. Available from: https://www.thermofisher.com/es/es/home/clinical/preclinical-companion-diagnostic-development/oncomine-oncology/oncomine-focus-assay.html
   Google Scholar
• Retribuciones del personal de Centros e Instituciones Sanitarias. ODG [Internet]. Juntadeandalucia.es. [ cited 2021 Dec 10]. Available from: https://www.sspa.juntadeandalucia.es/servicioandaluzdesalud/sites/default/files/sincfiles/wsas-media-sas_normativa_mediafile/2021/Resolucion_0001_2021_Retribuciones.pdf
   Google Scholar
• BOLETÍN OFICIAL DEL ESTADO de. Sec. III. Pág. N 174 L 22 de J. Boe.es [Internet]. 2019. [cited 2021 Dec 10]. Available from 2021 Dec 10. https://www.boe.es/eli/es/res/2019/07/09/(3)/dof/spa/pdf
   Google Scholar
• Gisbert R, Brosa M Healthcare cost database eSalud [Internet]. Oblikue.com. [ cited 2021 Dec 10]. Available from: http://www.oblikue.com/bddcostes/
   Google Scholar
• de Sanidad M, Consumo y Bienestar Social - Profesionales - Servicios - Medicamentos [Internet]. Gob.es. [ cited 2021 Dec 10]. Available from: https://www.mscbs.gob.es/profesionales/farmacia/notasInfor.htm
   Google Scholar
• Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics [Internet]. 2000;17(5):479–500.
   PubMed Web of Science ®Google Scholar
• Bernicker EH, Allen TC, Cagle PT. Update on emerging biomarkers in lung cancer. J Thorac Dis [Internet]. 2019;11(S1):S81–8.
   PubMedGoogle Scholar
• Li Y, Arellano AR, Bare LA, et al. A multigene test could cost-effectively help extend life expectancy for women at risk of hereditary breast cancer. Value Health [Internet]. 2017;20(4):547–555.
   PubMed Web of Science ®Google Scholar
• Signorovitch J, Janku F, Wheler JJ, et al. Estimated cost of anticancer therapy directed by comprehensive genomic profiling (CGP) in a single-center study. J Clin Oncol [Internet]. 2017;35(15_suppl):6605.
   Google Scholar
• Steuten L, Goulart B, Meropol NJ, et al. Cost effectiveness of multigene panel sequencing for patients with advanced non-small-cell lung cancer. JCO Clin Cancer Inform [Internet]. 2019;3(3):1–10.
   PubMedGoogle Scholar
• Yencho SW, Austin J, Betka E, et al. Cancer healthcare utilization impact of precision therapeutics: hospitalization/emergency visits.Cancer Sci Res [Internet]. 2020;3(3). 10.33425/2639-8478.1052.
   Google Scholar
• Baggi A, Bonetti G, Gancitano G, et al. Pcn177 organizational and economic impact of next generation sequencing and hotspot approach. Value Health [Internet]. 2019;22:S470.
   Web of Science ®Google Scholar
• Dalal AA, Guerin A, Mutebi A, et al. Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer. J Med Econ [Internet]. 2018;21(7):649–655.
   PubMed Web of Science ®Google Scholar
• Simarro J, Murria R, Pérez-Simó G, et al. Development, implementation and assessment of molecular diagnostics by next generation sequencing in personalized treatment of cancer: experience of a public reference healthcare hospital. Cancers (Basel) [Internet]. 2019;11(8):1196.
   Web of Science ®Google Scholar
• Ho R, Sebastião MM, D’Innocenzo M, et al. PPM4 cost-effectiveness analysis of next generation sequencing panel of circulating tumor DNA in the diagnosis of patient with metastatic non-squamous non- small cell lung cancer in Brazil. Value Health [Internet]. 2019;22:S333.
   Web of Science ®Google Scholar
• Schluckebier L, Caetano R, Garay OU, et al. Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients. BMC Cancer [Internet]. 2020;20(1):875.
   PubMed Web of Science ®Google Scholar
• Gómez JJ, de Castro J, Concha Á, et al. Recomendaciones para la determinación de biomarcadores en el carcinoma de pulmón no microcítico avanzado. Consenso nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica. Rev Esp Patol [Internet]. 2012;45:14–28.
   Google Scholar
• Vallejo-Torres L, García-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. Health Econ [Internet]. 2018;27(4):746–761.
   PubMed Web of Science ®Google Scholar
• Sacristán JA, Oliva J, Campillo-Artero C, et al. ¿Qué es una intervención sanitaria eficiente en España en 2020? Gac Sanit [Internet]. 2020;34(2):189–193.
   PubMed Web of Science ®Google Scholar
• Feng Y, Feng G, Lu X, et al. Exploratory analysis of introducing next-generation sequencing-based method to treatment-naive lung cancer patients. J Thorac Dis [Internet]. 2018;10(10):5904–5912.
   PubMed Web of Science ®Google Scholar